Current Edition

Pricing Pharmaceuticals in Japan

The year 2018 was epic for the Japanese pharmaceutical industry, largely because of the fundamental National Health Insurance (NHI) pricing reforms implemented in April, says Tosh Nagate at e-Projection K.K. The repercussions of this change in policy are yet to be fully felt as of the beginning of 2019; however, some of the cautionary signs can already be seen. For example, some domestic companies exited the market last year because of the unattractive prospects. This was unprecedented, particularly for a full-fledged domestic pharma company and it is difficult to imagine that these will be the only ones, with more moves expected in the coming months.